University of Pittsburgh researchers have developed a device for the removal of cell-free plasma hemoglobin from whole blood.
Description
Cell-free plasma hemoglobin is known to be toxic and detrimental to the body when not regulated within intact red blood cells, particularly during extracorporeal therapies such as cardiopulmonary bypass and extracorporeal life support. The current strategies for reducing plasma hemoglobin levels are limited and often require additional resources. This novel device utilizes a column containing small porous beads with an immobilized ligand that selectively and effectively removes plasma hemoglobin from whole blood within a standard extracorporeal circuit, and without the need for an extra blood pump. Therefore, the present invention is a significant advancement in the field of blood purification and has the potential to improve the management of plasma hemoglobin levels in extracorporeal therapies.
Applications
• Extracorporeal therapies
• Extracorporeal life support
• Cardiopulmonary bypass
Advantages
Prior developments in blood purification have shown varying success but are nonspecific in their removal of plasma proteins. The device is highly selective in its removal of plasma hemoglobin and can potentially be applied to other molecular targets. Additionally, this proposed device does not require additional staffing or resources, making it more efficient than current strategies.
Invention Readiness
Currently, the lab has a rodent sized device that we are testing in rat ECMO.
IP Status
https://patents.google.com/patent/WO2024015511A1
